SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Drug Development
Beyond Dr. Google: The Roles of Industry and AI in Fighting Misinformation and Fueling Patient Empowerment
As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount.
February 27, 2025
 · 
1 min read
 · 
Lori Ellis
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Editorial
The BioSpace Book Club Investigates the Biggest Deals of All Time
Our CEO accidentally started a book club. Now we’re all dreaming of mega pharma mergers.
February 26, 2025
 · 
3 min read
 · 
Annalee Armstrong
Gothenburg, Sweden – April 17, 2020: AstraZeneca in Gothenburg is one of three strategic global R&D centres in medicine. A big sign with the company logotype just outside the entrance.
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Health saving account, HSA, financial plan saving for medical expense or medicare cost and benefits concept, doctor with stethoscope standing with huge pink piggy bank or coin bank with medical sign.
GLP-1
As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using these therapies to treat conditions like heart disease risk that have existing cheap standards of care.
February 26, 2025
 · 
5 min read
 · 
Annalee Armstrong
Halftone hands reaching for money. Mixed media catch falling coins and cash bills collage, financial success, free wealth and easy money concept vector illustration
Funding
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
February 26, 2025
 · 
1 min read
 · 
Tristan Manalac
Astral Being Composed of Energy in Electromagnetic Spectrum
Rare diseases
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under the sun,” advocates say.
February 26, 2025
 · 
5 min read
 · 
Annalee Armstrong
Man searching paperwork in a huge filing cabinet, he is climbing on the open drawers using a ladder 3D illustration
Rare diseases
How To Mine Biopharma’s IP Storeroom for Rare Disease Drugs, Just Like SpringWorks
SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for every rare disease, experts say.
February 26, 2025
 · 
5 min read
 · 
Annalee Armstrong
Podcast
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.
February 26, 2025
 · 
1 min read
 · 
Heather McKenzie
External view of the U.S. Capitol building
Government
Congress Re-Introduces EPIC Act to Remove IRA’s ‘Pill Penalty’
While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it difficult for the current administration to make meaningful repeals or amendments to the IRA.
February 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS